Daniel J George

34PUBLICATIONS
123CO-AUTHORS
Molecular targetsPredictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Exercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Aug 05, 2026
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.

|Jul 10, 2026
Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.

|Jun 20, 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

|Apr 01, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

Santosh Gupta, Siyuan Guo, Susan Halabi

|Mar 19, 2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.

Neal D Shore, Daniel J George, Nasreen Khan

Pageof 6

Frequent Collaborators

15 joint publications

Andrew J Armstrong

7 joint publications

Susan Halabi

6 joint publications

Michael R Harrison

4 joint publications

Tian Zhang